Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase I Study to Evaluate the Safety and Efficacy of OBP-301 With Pembrolizumab in Patients With Advanced Solid Tumors

NCT03172819 is registered in ClinicalTrials.gov with Toshihiko Doi as lead sponsor.

NCT NCT03172819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03172819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase I Study to Evaluate the Safety and Efficacy of OBP-301 With Pembrolizumab in Patients With Advanced Solid Tumors
Lead sponsor
Toshihiko Doi
Phase
Phase 1
Overall status
Completed
Start date
October 1, 2017
Completion date
April 6, 2022
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor